Authors
Deepika, Komal Raj, Jyotsana Bhatt, Raghuraj Singh, Ashima Thakur, Charan Singh, Manoj Goyal, Ajay G Namdeo, Vijay Jyoti Kumar, Jayant Kumar
Published in
Current medical science. Nov 16, 2026. Epub Nov 16, 2026.
Abstract
Cuproptosis has recently attracted significant attention among oncologists. It occurs because of the accumulation of copper (Cu) within cells, leading to proteotoxicity and mitochondrial stress. Recent discoveries have highlighted the crucial role of Cu in the etiology of cancer, suggesting that Cu may be a promising therapeutic target. In this review, we provide a critical analysis of the tightly regulated levels of Cu in the body and cells. We focused on how Cu dysregulation contributes to the development and progression of cancers. The fundamental molecular mechanisms underlying cuproptosis, along with the cellular organelles involved, have been thoroughly examined. We have compiled recent studies on Cu-based therapies, including Cu chelators, Cu ionophores, and Cu complex-based dynamic therapies for cancer treatment. Additionally, we discuss small-molecule compounds and nanoparticles (NPs) that can induce cuproptosis to eliminate cancer cells, offering new insights for future anticancer drug development. Future research should focus on integrating cuproptosis-based therapies into current cancer treatment regimens to maximize patient response and minimize therapeutic resistance. This review suggests that targeting cuproptosis could serve as a novel therapeutic approach for antitumor treatment, providing strategies to overcome resistance to existing anticancer therapies.
PMID:
43037947
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0